Study Shows High Adherence in People on CDK 4/6 Inhibitors
Since 2015, three cyclin-dependent kinase (CDK) 4/6 inhibitors have come onto the U.S. market as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. A recently released poster from AllianceRx Walgreens Prime in collaboration with Duquesne University School of Pharmacy shows that people taking the therapies have high adherence, low rates of stopping treatment and low side effects.
Breast cancer is the second most commonly diagnosed cancer in women in the U.S. HR+/HER2- is the most common form of the condition, making up about 60% of breast cancer diagnoses. The National Comprehensive Cancer Network designates the CDK 4/6 inhibitors with an aromatase inhibitor or fulvestrant as category 1 first-line therapies for HR+/HER2- advanced or metastatic breast cancer.
Related Posts

More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE